Portfolio company
Signase
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This biotechnology company develops small molecule inhibitors of cell replication pathways to treat cancer patients by inhibiting tumour growth.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
KyDo
This biotechnology company develops small molecule inhibitors for the treatment of cancer variants in oncology patients.
Signadori Bio
This biopharmaceutical company develops a monocyte-based cell therapy platform to treat patients with solid tumours.
Senex Biotechnology
This drug discovery company develops small-molecule inhibitors targeting gene regulation proteins for pharmaceutical partners and healthcare providers treating prostate and breast cancers.
InnoSign
This precision medicine firm develops mRNA-based pathway activity profiling tests to help pharmaceutical companies and physicians predict patient responses to targeted cancer therapies.
Type6
Type6 develops kinase inhibitors that stabilise proteins in inactive states to treat cancers for the pharmaceutical and drug development industries.
SciBrunch
This biotechnology company develops small-molecule anti-tumour drugs for pharmaceutical partners and patients with cancer.
ARase Therapeutics
This company develops small molecule drugs targeting ADP-ribose hydrolases for patients with various forms of cancer.
Sentinel Oncology
The company develops small molecule drug candidates to treat cancers and rare brain disorders for the pharmaceutical and biotechnology sectors.